PepGen Inc

NASDAQ:PEPG   4:00:00 PM EDT
14.96
+0.19 (+1.29%)
5:50:13 PM EDT: $14.96 0.00 (0.00%)
Products, Regulatory

PepGen Reports Positive Data From Phase 1 Trial Of PGN-EDO51 For Treatment Of Duchenne Muscular Dystrophy

Published: 09/28/2022 10:15 GMT
PepGen Inc (PEPG) - Pepgen Reports Positive Data From Phase 1 Trial of Pgn-edo51 for the Treatment of Duchenne Muscular Dystrophy.
Pepgen Inc - Pgn-edo51 Was Generally Well-tolerated.
Pepgen Inc - Pepgen Plans to Initiate a Phase 2a Multiple Ascending Dose (mad) Clinical Trial in Duchenne Muscular Dystrophy (dmd) Patients in 1h 2023.
Pepgen Inc - Data Supports Potential of Pepgen's Enhanced Delivery Oligonucleotide (edo) Platform in Neuromuscular Diseases.